Cargando…

Domatinostat Targets the FOXM1–Survivin Axis to Reduce the Viability of Ovarian Cancer Cells Alone and in Combination with Chemotherapeutic Agents

The deregulation of the FOXM1 transcription factor is a key molecular alteration in ovarian cancer, contributing to the development and progression of ovarian cancer via activation of the target genes. As such, FOXM1 is a highly attractive therapeutic target in the treatment of ovarian cancer, but t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakagawa-Saito, Yurika, Mitobe, Yuta, Suzuki, Shuhei, Togashi, Keita, Sugai, Asuka, Kitanaka, Chifumi, Okada, Masashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341571/ https://www.ncbi.nlm.nih.gov/pubmed/37445993 http://dx.doi.org/10.3390/ijms241310817

Ejemplares similares

HDAC Class I Inhibitor Domatinostat Preferentially Targets Glioma Stem Cells over Their Differentiated Progeny
por: Nakagawa-Saito, Yurika, et al.
Publicado: (2022)

Inhibition of the Phospholipase Cε–c-Jun N-Terminal Kinase Axis Suppresses Glioma Stem Cell Properties
por: Okada, Masashi, et al.
Publicado: (2022)

Antagonizing MDM2 Overexpression Induced by MDM4 Inhibitor CEP-1347 Effectively Reactivates Wild-Type p53 in Malignant Brain Tumor Cells
por: Mitobe, Yuta, et al.
Publicado: (2023)

The Novel MDM4 Inhibitor CEP-1347 Activates the p53 Pathway and Blocks Malignant Meningioma Growth In Vitro and In Vivo
por: Mitobe, Yuta, et al.
Publicado: (2023)

Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs
por: Sanomachi, Tomomi, et al.
Publicado: (2019)

Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction
por: Suzuki, Shuhei, et al.
Publicado: (2019)

Targeting Folate Metabolism Is Selectively Cytotoxic to Glioma Stem Cells and Effectively Cooperates with Differentiation Therapy to Eliminate Tumor-Initiating Cells in Glioma Xenografts
por: Okada, Masashi, et al.
Publicado: (2021)

Gemcitabine Cooperates with Everolimus to Inhibit the Growth of and Sensitize Malignant Meningioma Cells to Apoptosis Induced by Navitoclax, an Inhibitor of Anti-Apoptotic BCL-2 Family Proteins
por: Yamamoto, Masahiro, et al.
Publicado: (2022)

In vitro and in vivo anti-tumor effects of brexpiprazole, a newly-developed serotonin-dopamine activity modulator with an improved safety profile
por: Suzuki, Shuhei, et al.
Publicado: (2019)

Doxazosin, a Classic Alpha 1-Adrenoceptor Antagonist, Overcomes Osimertinib Resistance in Cancer Cells via the Upregulation of Autophagy as Drug Repurposing
por: Suzuki, Shuhei, et al.
Publicado: (2020)

Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

Dexamethasone Sensitizes Cancer Stem Cells to Gemcitabine and 5-Fluorouracil by Increasing Reactive Oxygen Species Production through NRF2 Reduction
por: Suzuki, Shuhei, et al.
Publicado: (2021)

JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells
por: Suzuki, Shuhei, et al.
Publicado: (2014)

Inhibition of the Lipid Droplet–Peroxisome Proliferator-Activated Receptor α Axis Suppresses Cancer Stem Cell Properties
por: Kuramoto, Kenta, et al.
Publicado: (2021)

Therapeutic targeting of pancreatic cancer stem cells by dexamethasone modulation of the MKP-1–JNK axis
por: Suzuki, Shuhei, et al.
Publicado: (2021)

Repositioning CEP-1347, a chemical agent originally developed for the treatment of Parkinson’s disease, as an anti-cancer stem cell drug
por: Okada, Masashi, et al.
Publicado: (2017)

Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

Involvement of GLUT1-mediated glucose transport and metabolism in gefitinib resistance of non-small-cell lung cancer cells
por: Suzuki, Shuhei, et al.
Publicado: (2018)

Targeting the K-Ras - JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation
por: Okada, Masashi, et al.
Publicado: (2014)

Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells
por: Shibuya, Keita, et al.
Publicado: (2014)

HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation
por: Roca, Maria Serena, et al.
Publicado: (2022)

Correction to: HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation
por: Roca, Maria Serena, et al.
Publicado: (2022)

Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME)
por: Bretz, Anne Catherine, et al.
Publicado: (2019)

Elucidating the mechanism of action of domatinostat (4SC-202) in cutaneous T cell lymphoma cells
por: Wobser, Marion, et al.
Publicado: (2019)

The novel JNK inhibitor AS602801 inhibits cancer stem cells in vitro and in vivo
por: Okada, Masashi, et al.
Publicado: (2016)

Licochalcone A specifically induces cell death in glioma stem cells via mitochondrial dysfunction
por: Kuramoto, Kenta, et al.
Publicado: (2017)

Analysis of survivin, XIAP and FoxM1 as potential chemoresistance factors in breast cancer cells
por: Moraes, Gabriela N, et al.
Publicado: (2013)

The HDAC inhibitor domatinostat induces type I interferon α in Merkel cell carcinoma by HES1 repression
por: Srinivas, Nalini, et al.
Publicado: (2023)

Antitumor activity of gemcitabine against high-grade meningioma in vitro and in vivo
por: Takeda, Hiroyuki, et al.
Publicado: (2017)

TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters
por: Schneiderman, Rosa S, et al.
Publicado: (2010)

ET-6 Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

The over-expression of survivin enhances the chemotherapeutic efficacy of YM155 in human hepatocellular carcinoma
por: Xia, Hongping, et al.
Publicado: (2015)

Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis
por: Tang, Jun-Hai, et al.
Publicado: (2019)

Targeting JNK for therapeutic depletion of stem-like glioblastoma cells
por: Matsuda, Ken-ichiro, et al.
Publicado: (2012)

Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance
por: Voges, Yvonne, et al.
Publicado: (2016)

Neonatal rebound hyperkalemia associated with ritodrine alone: a case report
por: Osumi, Keita, et al.
Publicado: (2021)

FAT10 promotes chemotherapeutic resistance in pancreatic cancer by inducing epithelial-mesenchymal transition via stabilization of FOXM1 expression
por: Zhu, Jinfeng, et al.
Publicado: (2022)

Analysis of Dual Class I Histone Deacetylase and Lysine Demethylase Inhibitor Domatinostat (4SC-202) on Growth and Cellular and Genomic Landscape of Atypical Teratoid/Rhabdoid
por: Hoffman, Mariah M., et al.
Publicado: (2020)

FOXM1 is overexpressed in B-acute lymphoblastic leukemia (B-ALL) and its inhibition sensitizes B-ALL cells to chemotherapeutic drugs
por: CONSOLARO, FRANCESCA, et al.
Publicado: (2015)

FOXM1: Functional Roles of FOXM1 in Non-Malignant Diseases
por: Zhang, Zhenwang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ts2dm6kaacr2n84b2jjktiqm7n